Writing for Adgully, Paliwal looks at how shifting appetites from GLP-1 use are changing wellness spending in India.
Recap by typeshit. Post by Adgully on X.
Novo also reported 25% average weight loss in women on CagriSema in a post-hoc trial analysis, while BMO flagged Ozempic losing US share.
Dr. Nadolsky responds to a clip from comedian @stavvybaby2 about GLP-1s, adding a doctor's view to the joke.
He calls GLP-1 drugs useful before surgery or after regain, but says surgery stays the main option for people who need large, lasting weight loss.
An anonymous poster says people put their dramatic weight loss down to their mother's death, when it was really Ozempic they wanted to keep quiet.
Ott covered emerging vaccine-style approaches using peptides, DNA and mRNA at a special symposium on melanoma.
Demand for protein is climbing alongside GLP-1 use, and Reuters reports shoppers are looking harder at what those products actually deliver.
Loading…